

**Table 4: HLA- A\*03010101-07, 09-11N, 13-16 allele showing significant variations between breast cancer patients and controls.**

HLA- A*03010101-07,09-11N,13-16	Patients		Controls		Statistical evaluations		
	N	%	N	%	Odds ratio	EF	P
Breast cancer patients vs. healthy controls	15	50	3	16.6	5	0.40	0.041
Breast cancer patients vs. benign breast lesion patients	15	50	1	8.3	11	0.45	0.024

EF: Etiological fraction; P: Fisher's exact two-sided Probability.

### References

- Ackerman LV, Rosai J. Breast In: Rosai and Ackerman's Surgical Pathology, 9<sup>th</sup> ed, Ackerman LV and Rosai J (eds), Mosby, St Louis, 2004; pp1764-1824.
- ICB. Results of Iraqi National Cancer Registry, (1975-1978; 1989-1991; 1995-1997, 1998-2000). Iraqi Cancer Board ICRC, Ministry of Health Baghdad- Iraq; 2000.
- Shankarkumar U, Ghosh K, Badkere S, Mohanty D. Novel HLA Class I Alleles Associated with Indian leprosy Patients. J Biomed Biotechnol 2003; 3:208-211.
- Ferguson TA, Green DR, Griffith TS. Cell death and immune privilege. Int Rev Immunol 2002; 21: 153-172.
- Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2002; 2:277-288.
- Pellegris G, Illeni MT, Vaglini M. HLA antigens in malignant melanoma patients. Tumori, 1980; 66: 51-58.
- Bidwell JL, Soong TW, Raymond PA. HLA genotyping of colorectal carcinoma in the Chinese population. Hum Immunol 1992; 34:19- 23.
- Wu MS, Hsieh RP, Huang SP. Association of HLA-DQB1\*0301 and HLA-DQB1\*0602 with different subtypes of gastric cancer in Taiwan. Jpn J Cancer Res, 2002; 93:404-410.
- Harrath AB, Loueslati BY, Troudi W, Hmida S, Sedkaoui S, Dridi A, Jridi A. HLA class II polymorphism: Protective or risk factors to breast cancer in Tunisia Pathology. Oncology Research 2006; 12, No (2), 79-81.
- Glaser S. Immune -function genes and racedifferences in breast cancer. NorthernCaliforniaCancerCenter;2002.http://www.cbcrp.org/research/PageGrant.asp?grant\_id=2275.
- Glaser S, Join EM, Clarke CA, Erlich HA. Human leukocyte antigen genotype as a contributor to racial/ethnic differences in breast cancer: A population – based, molecular epidemiologic study. Northern california cancer center unioncity 2004; Annual rept 2 June 2003-1 June 2004.
- Miller SA, Dykes DD, Polesky IF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988; 16:1215.
- Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with PCR-SSP in two hours. Tissue Antigens 1992; 39:225-235.
- Olerup O, Zetterquist H. DR low-resolution PCR-SSP typing-a correction and an update. Tissue Antigens 1993; 41:55-56.
- Emery AEH. Methodology in medical genetics: An introduction to statistical methods. First edition, UK, Churchill Livingstone 1976; 98-102.
- Sorlie DE. Medical biostatistics and epidemiology: Examination and Board review First ed, Norwalk, Connecticut, Appleton and Lange 1995; 47-88.
- Fossum B, Breivik J, Meling GL. A K-ras 13Gly-->Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer Modifying effect of DQ7 on established cancers harboring this mutation. Int J Cancer 1994; 58, 506-11.
- Bateman A, Howell WM. Human leukocyte antigens and cancer: is it in our genes. J Pathol, 1999; 188: 231-6.
- Gopalkrishnan L, Patil S, Chhaya S, Badwe R, Joshi N. HLA alleles in pre-